Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Heart Failure × dapagliflozin × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 10 Polycystic Ovary Syndrome 4 Prostatic Neoplasms 2 Solid Tumors 1 Pediatric Brain Tumor 1 Pancreatic Neoplasms 1 Obesity 1 Inflammation 1 Hyperinsulinism 1 Hyperglycemia 1 Hereditary Sensory and Autonomic Neuropathies 1 Heart Failure 1 Diabetes Mellitus, Type 2 1 Diabetes Mellitus 1 Cardiotoxicity 1

Interventions

Exercise 3 sacubitril and valsartan sodium hydrate drug combination 2 Standard of Care 2 Rituximab 2 Nutrition Assessment 2 Ivabradine 2 Control Groups 2 Carvedilol 2 Atorvastatin 2 pertuzumab 1 pegfilgrastim 1 obinutuzumab 1 nicotinamide-beta-riboside 1 empagliflozin 1 dapagliflozin 1 candesartan 1 acalabrutinib 1 Vincristine 1 Valsartan 1 Trastuzumab 1 Surveys and Questionnaires 1 Spironolactone 1 Sodium Chloride 1 Simendan 1 Secondary Prevention 1 Pyruvic Acid 1 Prednisolone 1 Practice Guidelines as Topic 1 Population Groups 1 Perindopril 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07245069 2025-11-24

Alpaca

University Medical Centre Ljubljana

Phase 2 Recruiting

Breast Neoplasms, Heart Failure, Inflammation

Data powered by HemOnc (CC BY 4.0) Colophon ⚡